drugset

Drugs / autologous CAR.CD30 EBV specific-CTLs

Follow last change May 2012 re-read 3 minutes ago

autologous CAR.CD30 EBV specific-CTLs

also known as CD30 chimeric receptor EBV CTLs · CTLs CAR.CD30

Developed for: Hodgkins lymphoma · non-Hodgkin lymphoma
Investigated by: Baylor College of Medicine · Center for Cell and Gene Therapy, Baylor College of Medicine · The Methodist Hospital Research Institute

Trials 1

today NCT01192464 · Ph 1

20112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT01192464	May 2011 → May 2012 overdue	Hodgkins lymphoma, non-Hodgkin lymphoma	Baylor College of Medicine	Active not recruiting	No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	autologous CAR.CD30 EBV specific-CTLs	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01192464 ↗
Known as	CD30 chimeric receptor EBV CTLs	“We call the final cells CD30 chimeric receptor EBV CTLs.” NCT01192464 ↗
Known as	CTLs CAR.CD30	“Group One Dose (CTLs CAR.CD30) at Day 0: 2x10\^7 cells/m2” NCT01192464 ↗
Action	Deplete	“recognize and kill lymphoma cells” NCT01192464 ↗
Modality	Cell therapy	“We call the final cells CD30 chimeric receptor EBV CTLs.” NCT01192464 ↗
Route	Other	“Each patient will receive one injection.” NCT01192464 ↗